Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool For Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis
Autor: | Victoria Hans, Petra C E Hissink Muller, Annet van Royen-Kerkhof, Lauren M. Pachman, Femke van Wijk, Maria C. Amoruso, Esther P A H Hoppenreijs, Thaschawee Arkachaisri, Gabrielle A. Morgan, Wineke Armbrust, Kyra A. Gelderman, J. Merlijn van den Berg, Judith Wienke, Sylvia Kamphuis, Joo Guan Yeo |
---|---|
Přispěvatelé: | Paediatric Infectious Diseases / Rheumatology / Immunology, AII - Amsterdam institute for Infection and Immunity, Pediatrics |
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Galectin 1 DISEASE-ACTIVITY Polymyositis Gastroenterology Cohort Studies 0302 clinical medicine Immunology and Allergy Endothelial dysfunction Child Juvenile dermatomyositis UNTREATED DISEASE Endoglin ALPHA MONOCLONAL-ANTIBODY ASSOCIATION Pediatric Rheumatology Intercellular Adhesion Molecule-1 Prognosis POLYMYOSITIS Child Preschool Cohort Biomarker (medicine) Original Article Female Immunosuppressive Agents Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] HIGH EXPRESSION medicine.medical_specialty Galectins Immunology MEMBRANE ATTACK COMPLEX Dermatomyositis 03 medical and health sciences Rheumatology Internal medicine medicine Humans Receptors Tumor Necrosis Factor Type II Proportional Hazards Models Inflammation 030203 arthritis & rheumatology Duration of Therapy Proportional hazards model business.industry MUSCLE-TISSUE Endothelial Cells IN-VITRO medicine.disease Chemokine CXCL13 GALECTIN-1 Chemokine CXCL10 030104 developmental biology Chemokine CCL19 Endothelium Vascular Tumor necrosis factor receptor 2 business Biomarkers |
Zdroj: | Arthritis & rheumatology (Hoboken, N.J.), 72(7), 1214-1226. John Wiley and Sons Ltd ARTHRITIS & RHEUMATOLOGY, 72(7), 1214-1226. John Wiley & Sons Ltd. Arthritis & Rheumatology, 72, 1214-1226 Arthritis & Rheumatology, 72(7), 1214-1226. Wiley Arthritis & Rheumatology, 72, 7, pp. 1214-1226 Arthritis and Rheumatology, 72(7), 1214-1226. WILEY Arthritis & Rheumatology (Hoboken, N.j.) |
ISSN: | 1529-0131 2326-5191 |
Popis: | Contains fulltext : 220769.pdf (Publisher’s version ) (Open Access) OBJECTIVE: Juvenile dermatomyositis (DM) is a heterogeneous systemic immune-mediated vasculopathy. This study was undertaken to 1) identify inflammation/endothelial dysfunction-related biomarker profiles reflecting disease severity at diagnosis, and 2) establish whether such biomarker profiles could be used for predicting the response to treatment in patients with juvenile DM. METHODS: In total, 39 biomarkers related to activation of endothelial cells, endothelial dysfunction, and inflammation were measured using multiplex technology in serum samples from treatment-naive patients with juvenile DM from 2 independent cohorts (n = 30 and n = 29). Data were analyzed by unsupervised hierarchical clustering, nonparametric tests with correction for multiple comparisons, and Kaplan-Meier tests with Cox proportional hazards models for analysis of treatment duration. Myositis-specific antibodies (MSAs) were measured in the patients' serum using line blot assays. RESULTS: Severe vasculopathy in patients with juvenile DM was associated with low serum levels of intercellular adhesion molecule 1 (Spearman's rho [rs ] = 0.465, P = 0.0111) and high serum levels of endoglin (rs = -0.67, P < 0.0001). In the discovery cohort, unsupervised hierarchical clustering analysis of the biomarker profiles yielded 2 distinct patient clusters, of which the smaller cluster (cluster 1; n = 8) exhibited high serum levels of CXCL13, CCL19, galectin-9, CXCL10, tumor necrosis factor receptor type II (TNFRII), and galectin-1 (false discovery rate |
Databáze: | OpenAIRE |
Externí odkaz: |